14 unknown, 6 recruiting, 5 not yet recruiting, 4 completed. 8 Phase 2, 5 Not applicable, 5 Phase 3, 2 Early Phase 1, 2 Phase 1.
Follow Changzhou No.2 People's Hospital: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma - DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 40 | 2026-08-30 | 2026-08-06 |
| A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma Iparomlimab and Tuvonralimab in combination with Lenvatinib - Urologic Neoplasms | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 54 | 2026-08-15 | 2026-08-03 |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Pirtobrutinib+Pola-R-CHP - DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 48 | 2026-07-31 | 2026-08-06 |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Pirtobrutinib plus R-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 34 | 2026-07-30 | 2026-08-06 |
| A Survey of Public Attitudes Towards Gallbladder-preserving Lithotomy and Its Influencing Factors Cholecystolithiasis | Recruiting | Changzhou No.2 People's Hospital | 5000 | 2026-07-21 | 2026-10-02 | |
| Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) Mazdutide, Placebo - Dementia, Mild, Mild Cognitive Impairment | Phase 3 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 420 | 2025-09-27 | 2026-09-02 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial Steerable FANS, Conventional FANS - Kidney Stones | Not applicable | Recruiting | The First Affiliated Hospital of Guangzhou Medical University | 400 | 2025-03-16 | 2025-03-27 |
| An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia anti-CD19 CAR NK cells (KN5501) - Thrombocytopenia Alloimmune | Early Phase 1 | Recruiting | Changzhou No.2 People's Hospital | 9 | 2024-08-30 | 2025-04-30 |
| γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors γδ T-PD-1 Ab cells - Advanced Solid Tumor | Phase 1 | Unknown | Changzhou No.2 People's Hospital | 9 | 2024-08-01 | 2024-08-22 |
| Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407) TACE, HCC - Hepatocellular Carcinoma | Unknown | Shengjing Hospital | 400 | 2024-06-30 | 2024-07-03 | |
| FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy - Non-small Cell Lung Cancer | Phase 2 | Unknown | Changzhou No.2 People's Hospital | 62 | 2024-06-01 | 2024-12-20 |
| FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy - Gastric Cancer | Phase 2 | Recruiting | Changzhou No.2 People's Hospital | 198 | 2024-06-01 | 2025-02-20 |
| An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma NKG2D Chimeric Antigen Receptor NK Cell Injection - Multiple Myeloma | Early Phase 1 | Unknown | Changzhou No.2 People's Hospital | 9 | 2024-04-18 | 2024-04-23 |
| Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters Multimedia Health Education - Vitreous Floaters, Anxiety | Not applicable | Recruiting | Changzhou No.2 People's Hospital | 300 | 2023-12-01 | 2025-05-14 |
| LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes Liraglutide, Empagliflozin, Linagliptin - Type 2 Diabetes Mellitus, Mild Cognitive Impairment | Not applicable | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 396 | 2022-10-08 | 2026-08-06 |
| Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients Laboratory analysis of samples - FH-Deficient RCC, Systemic Treatments | Unknown | RenJi Hospital | 100 | 2022-08-01 | 2023-08-31 | |
| Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus Dislocated Lens, Pars Plana Vitrectomy | Completed | Changzhou No.2 People's Hospital | 9 | 2022-07-01 | 2024-11-29 | |
| The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP - Diffuse Large B-Cell Lymphoma | Phase 3 | Unknown | Ruijin Hospital | 280 | 2022-03-02 | 2023-05-23 |
| Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients Decitabine plus HAAG regimen, Idarubicine plus Cytarabine regimen - Acute Myeloid Leukemia, Induction Chemotherapy | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 162 | 2019-04-01 | 2019-09-12 |
Showing 20 of 29. Sign in to see all of them.
Dendritic Cell Sarcoma, Interdigitating (3) · Diabetes Mellitus, Type 2 (3) · Cognitive Dysfunction (2) · Leukemia, Myeloid, Acute (2) · Anemia, Hemolytic, Autoimmune (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Anxiety Disorders (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholecystolithiasis (1) · Coronary Disease (1) · Dementia (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Health Education (1)
Decitabine (2) · Fecal Microbiota Transplantation (2) · pirtobrutinib (2) · Aclarubicin (1) · Chemoradiotherapy (1) · Cytarabine (1) · Gefitinib (1) · Granulocyte Colony-Stimulating Factor (1) · Homoharringtonine (1) · Idarubicin (1) · Lenalidomide (1) · Linagliptin (1) · Liraglutide (1) · Metformin (1) · Rituximab (1)
China (25)
Xiaowen Tang, Ph.D. (3) · Hua Jiang, MD (2) · Yan Bi, MD, PhD (2) · Dalong Zhu, MD, PhD (1) · Guohua Zeng, M.D. (1) · Liming Tang, doctor (1) · Min Tao, Doctor (1) · Minglong Chen, M.D. (1) · Sun Suping, M.D.,PhD. (1) · Xincheng Sun (1) · Xuzhang Lu, doctor (1) · Yi Chai, MD (1) · Yingbin Liu, MD, PhD (1)
PMID 29500313, PMID 30520221, PMID 31221697, PMID 33593763, PMID 34268122, PMID 35263425, PMID 40037667, PMID 40840993, PMID 41338650, PMID 42211675